Technetium-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals
- PMID: 1532419
Technetium-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals
Abstract
L,L-ethylenedicysteine (L,L-EC) can be labeled efficiently with 99mTc at pH 12 to obtain a highly pure and very stable tracer agent (99mTc-L,L-EC). The biological behavior of 99mTc-L,L-EC was studied in mice and a baboon. In mice, 99mTc-L,L-EC demonstrated a more rapid urinary excretion and less retention in the kidneys, the liver, the intestines, and the blood than did 99mTc-MAG3 at 10 and 60 min p.i. Urinary excretion decreased in probenecid pretreated mice, which indicates active tubular transport. In the baboon, the renograms for 99mTc-MAG3 and 99mTc-L,L-EC were comparable. Plasma-protein binding of 99mTc-L,L-EC was lower than that of 99mTc-MAG3 while its distribution volume and 1-hr plasma clearance were clearly higher. The promising results of the animal experiments suggest that 99mTc-L,L-ethylenedicysteine may be a useful alternative to 99mTc-MAG3 for renal function studies in humans.
Similar articles
-
Synthesis and biological evaluation of the four isomers of technetium-99m labeled ethylenecysteamine cysteine ((99m)Tc-ECC), the mono-acid derivative of (99m)tc-L,L-ethylenedicysteine.Nucl Med Biol. 2000 Feb;27(2):207-14. doi: 10.1016/s0969-8051(99)00092-x. Nucl Med Biol. 2000. PMID: 10773551 Clinical Trial.
-
Effect of protein binding on renal extraction of 131I-OIH and 99mTc-labeled tubular agents.J Nucl Med. 2000 Dec;41(12):2077-82. J Nucl Med. 2000. PMID: 11138695
-
First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent.Eur J Nucl Med. 1993 Sep;20(9):738-46. doi: 10.1007/BF00180902. Eur J Nucl Med. 1993. PMID: 8223766
-
Technetium-99m-EC and other potential new agents in renal nuclear medicine.Semin Nucl Med. 1999 Apr;29(2):91-101. doi: 10.1016/s0001-2998(99)80002-6. Semin Nucl Med. 1999. PMID: 10321823 Review.
-
Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent.Semin Nucl Med. 1992 Apr;22(2):61-73. doi: 10.1016/s0001-2998(05)80082-0. Semin Nucl Med. 1992. PMID: 1534184 Review.
Cited by
-
Technetium-99m-L,L-ethylenedicysteine scintigraphy in patients with renal disorders.Eur J Nucl Med. 1995 Jul;22(7):617-24. doi: 10.1007/BF01254562. Eur J Nucl Med. 1995. PMID: 7498222 Clinical Trial.
-
A brief overview of metal complexes as nuclear imaging agents.Dalton Trans. 2019 Oct 7;48(39):14547-14565. doi: 10.1039/c9dt03039e. Dalton Trans. 2019. PMID: 31556418 Free PMC article. Review.
-
Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):115-21. doi: 10.1007/s00259-008-0925-8. Epub 2008 Aug 16. Eur J Nucl Med Mol Imaging. 2009. PMID: 18709369
-
Evaluation of differential renal function in children - a comparative study between magnetic resonance urography and dynamic renal scintigraphy.BMC Pediatr. 2024 Mar 25;24(1):213. doi: 10.1186/s12887-024-04694-2. BMC Pediatr. 2024. PMID: 38528521 Free PMC article.
-
First evaluation of a 99mTc-tricarbonyl complex, 99mTc(CO)3(LAN), as a new renal radiopharmaceutical in humans.J Nucl Med. 2006 Jun;47(6):1032-40. J Nucl Med. 2006. PMID: 16741314 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources